News ProMIS Neurosciences, Inc.

Equities

PMN

CA74346M4065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-13 pm EDT			5-day change	1st Jan Change
2 ^USD	+5.82%		-2.43%	+73.91%

Apr. 30	ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	CI
Apr. 09	ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	Apr. 30	AQ
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	Apr. 30	CI
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	Apr. 09	AQ
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	Apr. 09	CI
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	Apr. 05	AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	Apr. 04	AQ
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	Apr. 01	AQ
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
ProMIS Neurosciences : Corporate Overview	Mar. 29	PU
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	Mar. 11	AQ
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	Feb. 22	AQ
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	Jan. 22	AQ
ProMIS Neurosciences Issues Letter to Shareholders	Jan. 08	AQ
ProMIS Neurosciences, Inc. Announces Management Changes	Jan. 03	CI
ProMIS Neurosciences, Inc. Announces CEO Changes	Jan. 03	CI
ProMIS Neurosciences, Inc. Announces Leadership Transition	Jan. 03	AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	CI
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	Nov. 20	AQ
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	Nov. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ProMIS Neurosciences, Inc.

Equities

PMN

CA74346M4065

Summary

Filters